Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

e its goal of having no more than 5% of

patients lost to follow-up at the time of the week 72

assessment.

ITMN-191:

-- On April 2, InterMune reported top-line results in the four dose

cohorts of treatment-naive patients chronically infected with

hepatitis C virus (HCV) genotype 1 in its Phase 1b multiple-

ascending-dose (MAD) monotherapy trial of ITMN-191:

-- Day 14 median viral kinetic results competitive with those

published for other direct antiviral compounds when used in

monotherapy for 14 days. Specifically, InterMune reported a

median 3.8 log reduction (equal to 99.98% reduction) in HCV RNA

from baseline at Day 14;

-- Significant and rapid viral kinetic activity when dosed every

12 hours; and

-- Excellent safety and tolerability in all dosage regimens.

-- InterMune reported successful completion of 13-week toxicology

studies in rats and monkeys at exposures higher than those expected

to be evaluated in clinical studies. These preclinical studies were

required before initiating the Phase 2 program of ITMN-191 which

will involve durations of therapy longer than those studied in Phase

1.

-- Announced on May 29 the initiation of a 14-day study of ITMN-191 in

combination with Pegasys(R) (pegylated interferon alpha-2a) and

Copegus(R) (ribavirin). The study is proceeding as planned.

-- Submitted several abstracts for possible presentation at the 59th

Annual Meeting of the American Association for the Study of Liver

Diseases (AASLD) to be held October 31 - November 4, 2008 in San

Francisco, including but not limited to data on ITMN-191.

Financial:

-- On June 24, InterMune exchanged $85 million
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... , April 23, 2015 /PRNewswire/ - Crystal Research Associates, ... Informational Overview ® (EIO) on Aeterna Zentaris Inc. ... is available on Crystal Research Associates, website at ... Zentaris, website at www.aezsinc.com . Aeterna ... specialty biopharmaceutical company in oncology, endocrinology, and women,s health. ...
(Date:4/22/2015)... , April 22, 2015  Sangamo BioSciences, Inc. ... 2015 financial results and accomplishments. For the ... consolidated net loss of $5.3 million, or $0.08 per ... or $0.12 per share, for the same period in ... cash, cash equivalents, marketable securities and interest receivable of ...
(Date:4/22/2015)... April 22, 2015 Steep Hill, the ... today that it has opened an investment round ... and expansion.  The common stock investment round will ... a law intended to encourage funding of small ... 506(c), small businesses largely relied on friends and ...
Breaking Biology Technology:Glemser Earns Accreditation for Life Sciences Solution Suite 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Agreement Enables Spherix to Pursue All Pharmaceutical and Health-Oriented ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has terminated the 1996 license agreement pursuant to ...
... SAO PAULO, June 23 What does sugarcane have ... successful,30-year experience with sugarcane as a feedstock for ethanol. In ... replace a fossil fuel with,renewable energy has saved some 600 ... years for six billion trees to achieve the same,results. , ...
... , Continuing Supplies Will Be Used For NDA and ... Type 2 Diabetes , , BETHESDA, Md., June ... an innovator in biotechnology for diabetes therapy, and a ... supplement, biotechnology and pharmaceutical companies, today announced that it ...
Cached Biology Technology:Spherix Announces Termination of Arla License Agreement 2Spherix Announces Termination of Arla License Agreement 3Spherix Announces Termination of Arla License Agreement 4Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 3Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 4Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... NT APRIL 2010 High in the Mackenzie Mountains, ... being revealed as warming temperatures melt patches of ice that ... Tom Andrews, an archaeologist with the Prince of Wales Northern ... Polar Year Ice Patch Study, is amazed at the implements ...
... April 26, 2010 Energy in, energy out, it,s the ... more than two thirds of Americans classified as overweight or ... Journal of Nutrition Education and Behavior examines how ... loss programs. Researchers at the University of Kentucky and ...
... 26 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader ... (OK) Sheriff,s Office successful deployment of an FBI-compliant advanced authentication solution for ... authentication. , , , ... http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , , , ...
Cached Biology News:Ancient artifacts reveals as northern ice patches melt 2What's motivation got to do with weight loss? 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 3BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 4
... 0.9 ml per liter of urine will give ... or BMD dipstick. ,Certification: The Donors are ... found to be NEGATIVE for HbsAg, HCV, HIV-1 ... approved FDA methods. THIS MATERIAL IS SOLD FOR ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... production by luciferase-cDNA transfected cell lines has ... the development of reporter gene assays in ... indicator for the transcription of other genes. ... due to advantages such as high sensitivity ...
... detection of apoptosis and mitochondrial membrane potential. ... early indication of the initiation of cellular ... a collapse in the electrochemical gradient across ... change in the membrane potential (YD). Loss ...
Biology Products: